Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.240
-0.100 (-7.46%)
At close: Apr 17, 2026, 4:00 PM EDT
1.280
+0.040 (3.19%)
After-hours: Apr 17, 2026, 7:31 PM EDT
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,426,778
Market Cap
158.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | -5 | -35.71% |
| Dec 31, 2021 | 14 | 3 | 27.27% |
| Dec 31, 2020 | 11 | 3 | 37.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Protalix BioTherapeutics | 226 |
| Fate Therapeutics | 161 |
| Heron Therapeutics | 128 |
| Agenus | 81 |
| Cartesian Therapeutics | 75 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
TLSA News
- 3 days ago - Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function - GlobeNewsWire
- 5 days ago - Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress - GlobeNewsWire
- 18 days ago - Tiziana Life Sciences Stock Jumps As Positive Preclinical Fuels Momentum - Benzinga
- 18 days ago - Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging - GlobeNewsWire
- 7 weeks ago - Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million - GlobeNewsWire